Cargando…
Nanotechnology-Based Histone Deacetylase Inhibitors for Cancer Therapy
Histone deacetylase inhibitors (HDACi) have been approved and achieved success in hematologic malignancies. But its application in solid tumors still confronts big challenges and is hampered by low treatment efficacy. Nanotechnology has been widely applied in cancer therapy, and nanomedicine could i...
Autores principales: | Tu, Bin, Zhang, Meng, Liu, Tuanbing, Huang, Yongzhuo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7284110/ https://www.ncbi.nlm.nih.gov/pubmed/32582697 http://dx.doi.org/10.3389/fcell.2020.00400 |
Ejemplares similares
-
Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020) -
The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy
por: Li, Guo, et al.
Publicado: (2020) -
Editorial: Epigenetic Therapy With Histone Deacetylase Inhibitors: Implications for Cancer Treatment
por: Sousa, Angela, et al.
Publicado: (2021) -
Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma
por: Yeon, Minjeong, et al.
Publicado: (2020) -
Histone Deacetylase Inhibitors in Pediatric Brain Cancers: Biological Activities and Therapeutic Potential
por: Perla, Alexandre, et al.
Publicado: (2020)